- Home
- KRON vs ELTX Comparison
KRON vs ELTX Comparison
Compare KRON & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- ELTX
- Stock Information
- Founded
- KRON 2017
- ELTX 2011
- Country
- KRON United States
- ELTX United States
- Employees
- KRON N/A
- ELTX N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- KRON Health Care
- ELTX Health Care
- Exchange
- KRON Nasdaq
- ELTX Nasdaq
- Market Cap
- KRON 60.3M
- ELTX 54.6M
- IPO Year
- KRON 2020
- ELTX 2021
- Fundamental
- Price
- KRON $0.97
- ELTX $5.01
- Analyst Decision
- KRON Buy
- ELTX Strong Buy
- Analyst Count
- KRON 3
- ELTX 3
- Target Price
- KRON $1.63
- ELTX $9.50
- AVG Volume (30 Days)
- KRON 384.9K
- ELTX 32.5K
- Earning Date
- KRON 11-13-2024
- ELTX 11-13-2024
- Dividend Yield
- KRON N/A
- ELTX N/A
- EPS Growth
- KRON N/A
- ELTX N/A
- EPS
- KRON N/A
- ELTX N/A
- Revenue
- KRON $9,864,000.00
- ELTX N/A
- Revenue This Year
- KRON $62.21
- ELTX N/A
- Revenue Next Year
- KRON N/A
- ELTX N/A
- P/E Ratio
- KRON N/A
- ELTX N/A
- Revenue Growth
- KRON 146.48
- ELTX N/A
- 52 Week Low
- KRON $0.69
- ELTX $2.96
- 52 Week High
- KRON $1.60
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- KRON 52.82
- ELTX 49.24
- Support Level
- KRON $0.92
- ELTX $4.85
- Resistance Level
- KRON $1.03
- ELTX $5.14
- Average True Range (ATR)
- KRON 0.06
- ELTX 0.32
- MACD
- KRON -0.00
- ELTX -0.03
- Stochastic Oscillator
- KRON 44.16
- ELTX 30.25
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.